Daniel Oren

MD|MSc | Instructor in Medicine @Columbia University Center for Advance Cardiac Care

[Andrea Fernandez Valledor, MD @andreavalledor1]

One step further🪜Subclinical injury isn’t benign. 1/3 of “negative” biopsies with ↑ dd-cfDNA revealed rejection on MMDx. Moving toward a new era of molecular surveillance. @CathMoellerMD @Daniel_OrenMD @NirUrielMD @Columbia

[Andrea Fernandez Valledor, MD @andreavalledor1]

Our latest at @TheJHLT

Correlation between dd-cfDNA and MMDx in HTx undergoing for-cause endomyocardial biopsies

MMDx detected rejection 4x > than histology when dd-cfDNA was elevated—mainly ABMR

📈 dd-cfDNA AUC 0.89
📌 Opt=0.26%

🔗 https://t.co/xoA0k0fEuV

#CardioX

[Circ: Heart Failure @CircHF]

What if dd-cfDNA is elevated but there is no evidence of rejection? Consider flow-limiting CAV. We found that reduced myocardial blood flow was associated with elevations in dd-cfDNA, with or without epicardial CAV @NirUrielMD @Daniel_OrenMD
https://t.co/p7kvugWkqT

[Daniel Oren @Daniel_OrenMD]

Trainees at every level don’t miss this opportunity to learn from leaders in the field!

[Nir Uriel, MD MSc @NirUrielMD]

There is still time to register and attend our @NYPCUCVI Heart Transplant Summit this Friday 6/23

The latest updates in Heart Transplantation. Don’t miss it!

Link to register: https://t.co/ppJnm6vwh1

[Nir Uriel, MD MSc @NirUrielMD]

There is still time to register and attend our @NYPCUCVI Heart Transplant Summit this Friday 6/23

The latest updates in Heart Transplantation. Don’t miss it!

Link to register: https://t.co/ppJnm6vwh1

[Daniel Oren @Daniel_OrenMD]

Congratulations @dor_lotan and team! @CathMoellerMD @gal_rubinstein

[Dor Lotan, MD @dor_lotan]

I was honored to present our work discussing the effect of preservation modality on the myocardial injury. In this study, we compared Ice to Sherpapak and looked at ischemic injury for up to 8 weeks. @NirUrielMD @gtsayer @ersied727 @Daniel_OrenMD #ISHLT2023 @ParagonixSherpa

[Daniel Oren @Daniel_OrenMD]

A great 1st day @ISHLT2023 had a great time presenting our work on dd-cfDNA in HT recipients with micro vascular CAV. Huge thanks to the entire Columbia team and to my mentors, coauthors, and friends.

[Dor Lotan, MD @dor_lotan]

��📰🫀Let’s start! Some of our studies presented today at #ISHLT2023 #ddcfdna @NirUrielMD @gtsayer @Daniel_OrenMD @ersied727 @VeliKTopkaraMD @Justin_FriedMD

[JACC Journals @JACCJournals]

Data on the use of CAR-T cell therapy in solid organ transplant recipients are limited. Check out this interesting case of refractory post-transplant lymphoproliferative disorder treated w/ #CARTcell therapy in #JACCCardioOnc: https://t.co/95VqlC0al4

#CardioOnc #Immunotherapy

[Dor Lotan, MD @dor_lotan]

A challenging case shows the importance of multidisciplinary teamwork! Combined Heart and Liver Transplantation in a Patient Supported by Left Ventricular Assist Device (LVAD) with Propionic Acidemia https://t.co/62UN1faPds
@ColumbiaSurgery @ColumbiaMed @CUMCHeartSource

[Daniel Oren @Daniel_OrenMD]

@QRStradivarius לא יודע להגיד שזה תמיד רלוונטי ועוד פחות שבהכרח בארהב. לגבי התמחות כאן זה ודאי לא טריוויאלי אבל בהחלט לא בלתי אפשרי. אם זה משהו שאתה חושב עליו ברצינות אשמח לחלוק אינפורמציה ולעזור במה שאוכל.

[Daniel Oren @Daniel_OrenMD]

@QRStradivarius אם המטרה היא קידום מקצועי אז השאלה היא האם פלו/התמחות בארהב בעתיד רלוונטית. מחקר משמעותי יש גם בארץ. אם ה��שובה היא כן ומדובר במרכז אונברסיטאי גדול הייתי אומר 3 חודשים לפחות ומניסיוני בהחלט יש יתרון.

[Nir Uriel, MD MSc @NirUrielMD]

Excited for the second @nyphospital Cardio-Oncology summit taking place on January 19th from 12-5 PM

Highlights: experts panelists discussing management of cancer-related cordiotoxicity + adv HF management in cancer survivors

FREE registration + Agenda: https://t.co/ORiKKKJRaA

[Daniel Oren @Daniel_OrenMD]

Point of intersection of 🫀Tx and CAR T cell. Our clinical case challenge in @jacc CardioOnc ➡️our experience and the question of the future role of CAR T In the management of PTLD. Thankful to my mentors and coauthors @ersied727 @dor_lotan @NirUrielMD RanReshef, JayantRaikhelkar

[Daniel Oren @Daniel_OrenMD]

https://t.co/TcTyLOSo2R

[Daniel Oren @Daniel_OrenMD]

Happy to share our new review of temporary MCS, as a bridge to recovery or heart replacement therapy in patients with refractory cardiogenic shock. Huge thanks to my mentors and co-authors @dor_lotan, @RZilinyi, @NirUrielMD,@gtsayer #columbiacardio

[Columbia Surgery @ColumbiaSurgery]

First annual Heart Transplant Summit, led by @NirUrielMD happening next Friday! Lectures by internationally recognized experts, didactics, case presentations, & debates all with the goal of improving the management of patients w/ heart disease. Join us: https://t.co/SApa5fBHDp

[Daniel Oren @Daniel_OrenMD]

@co_yaron למען הדיוק נראה שמדובר ב composite של תמותה ו organ dysfunction

[Daniel Oren @Daniel_OrenMD]

Perspicacity- The excitement which comes from the intellectual exercise of understanding complex and hidden interactions. Research work can be incredibly dull and uninspiring at times. The search for the hidden or misunderstood preserves curiosity and protects against burnout.

[Daniel Oren @Daniel_OrenMD]

Proactive Serendipity - Great opportunities are more likely to come by when we put ourselves in a position for them to happen. In a less trivial sense, directing one's efforts to "risky" projects where the potential for something interesting or meaningful is substantial.